Retham Technologies
Research - Milwaukee, Wisconsin, United States
Retham Technologies Employees
Retham Technologies Details
Retham Technologies™ LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT).HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputation, stroke and death. The diagnosis of HIT is challenging. A family of easy-to-run tests called PF4 ELISAs is performed in the hospital laboratory but have high false positive rates, i.e. many patients positive for antibodies to PF4:polyanion complexes do not have clinical HIT. A second test, the Serotonin release assay (SRA), is considered the "gold-standard" test for HIT; but, it is performed only at a handful of laboratories nationally on a small fraction of suspected cases due to technical complexity, cost and turnaround time concerns. Thus, >90% of HIT suspected patients are currently managed using PF4 ELISAs, and thousands of patients receive costly non-heparin anticoagulant therapy due to "false positive" diagnoses. These alternative anticoagulants have a worse bleeding risk profile relative to heparin often resulting in severe or fatal hemorrhage. Retham Technologies™ is developing HITDx™, an IVD assay for early and accurate near-patient HIT diagnosis that is expected to facilitate timely and appropriate therapy thereby leading to better outcomes.
Retham Technologies Technologies
Email Providers
Outlook
CMS
Wix
Other
Microsoft Office 365
Hosting
Google Cloud Hosting